

Supporting Information

Novel Anthraquinone Derivatives as Inhibitors of Protein Tyrosine Phosphatases and Indoleamine 2,3-Dioxygenase 1 from the Deep-sea Derived Fungus *Alternaria tenuissima* DFFSCS013

Dongyan Pan^{†, ‡}, Xuexia Zhang[§], Haizhou Zheng[§], Zhihui Zheng[§], Xuhua Nong,[†] Xiao Liang^{†, ‡}, Xuan Ma[†], Shuhua Qi^{†, *}

[†] CAS Key Laboratory of Tropical Marine Bio-resources and Ecology, Guangdong Key Laboratory of Marine Materia Medica, Institution of South China Sea Ecology and Environmental Engineering, South China Sea Institute of Oceanology, Chinese Academy of Sciences, 164 West Xingang Road, Guangzhou, 510301, Guangdong, China

[‡] University of Chinese Academy of Sciences, Beijing, 100049, China

[§] New Drug Research & Development Co., Ltd, North China Pharmaceutical Group Corporation, Shijiazhuang, Hebei 050015, China

List of contents

EXPERIMENTAL SECTION

Figure S1. ¹ H NMR spectrum of compound 1	
Figure S2. ¹³ C NMR spectrum of compound 1	
Figure S3. DEPT NMR spectrum of compound 1	
Figure S4. HSQC spectrum of compound 1	
Figure S5. HMBC spectrum of compound 1	
Figure S6. ¹ H- ¹ H COSY spectrum of compound 1	
Figure S7. NOESY spectrum of compound 1	
Figure S8. HRESIMS spectrum of compound 1	
Figure S9. IR spectrum of compound 1	
Figure S10. UV spectrum of compound 1	
Figure S11. Crystal data and structure refinement for compound 1	

Figure S12. ^1H NMR spectrum of compound 2	
Figure S13. ^{13}C NMR spectrum of compound 2	
Figure S14. DEPT NMR spectrum of compound 2	
Figure S15. HSQC spectrum of compound 2	
Figure S16. HMBC spectrum of compound 2	
Figure S17. ^1H - ^1H COSY spectrum of compound 2	
Figure S18. NOESY spectrum of compound 2	
Figure S19. HRESIMS spectrum of compound 2	
Figure S20. IR spectrum of compound 2	
Figure S21. UV spectrum of compound 2	
Figure S22. ^1H NMR spectrum of compound 3	
Figure S23. ^{13}C NMR spectrum of compound 3	
Figure S24. HMBC spectrum of compound 3	
Figure S25. COSY spectrum of compound 3	
Figure S26. NOESY spectrum of compound 3	
Figure S27. HRESIMS spectrum of compound 3	
Figure S28. IR spectrum of compound 3	
Figure S29. UV spectrum of compound 3	
Figure S30. Stimulation of calcium signaling in HEK293 cells by compound 1	
Table S1. Stable conformers of compounds 2 and 3 used for ECD calculation	
Table S2. Stable conformers of $(13R^*,18S^*)$ - 2 and their calculated ^{13}C NMR data used for the ^{13}C NMR calculation of $(13R^*,18S^*)$ - 2	
Table S3. Stable conformers of $(13S^*,18S^*)$ - 3 and their calculated ^{13}C NMR data used for the ^{13}C NMR calculation of $(13S^*,18S^*)$ - 3	
Table S4. DP4 ⁺ analysis result table for compound 2 (experimental for 2 , isomer 1 for $(13S^*,18S^*)$ - 3 , isomer 2 for $(13R^*,18S^*)$ - 2)	
Table S5. DP4 ⁺ analysis result table for compound 3 (experimental for 3 , isomer 1 for $(13S^*,18S^*)$ - 3 , isomer 2 for $(13R^*,18S^*)$ - 2)	


EXPERIMENTAL SECTION

Phosphatase Enzyme Inhibition Assays. Recombinant human phosphatase PTP1B, SHP1, SHP2, MEG2 and TCPTP were expressed in *Escherichia coli* and purified. The enzyme inhibition assays were measured using *p*-nitrophenyl phosphate (pNPP) as a substrate in a 96-well plate with a final volume of 100 μ L. Human recombinant PTP1B, SHP1, SHP2, MEG2 or TCPTP (0.05 μ g) in 50 μ L reaction buffer (pH 6.5) containing 50 mM HEPES, 100 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol (DTT) and test compounds were added to each well of a 96-well plate. Na_3VO_4 was used as the positive control and DMSO as the negative control to evaluate the high-throughput screening (HTS) system. After preincubation for 15 min at room temperature, 50 μ L of reaction buffer containing 50 mM pNPP was added and incubated at 37 $^\circ\text{C}$ for 60 min. The phosphatase activity was determined by measuring the absorbance at 405 nm for the amount of produced *p*-nitrophenol. IC_{50} values were determined by analyzing the data using Gen5 software (Synergy2 Multi-Mode Microplate Reader, BioTek Instruments, Inc.). Each compound was assayed in triplicate.

IDO Enzyme Inhibition Assays. Recombinant human IDO was expressed in *E. coli* and purified. Briefly, the reaction mixture (200 μ L) contained potassium phosphate buffer (50 mM, pH 6.5), ascorbic acid (10 mM), methylene blue (5 μ M), purified recombinant IDO1 (43 μ M), L-Trp (100 μ M), and DMSO (10 μ L). The inhibitors were serially diluted 3-fold from 50 to 0.02 mM in pure DMSO. The reaction was conducted at 37 $^\circ\text{C}$ for 6 min and stopped by addition of 30% (w/v) trichloroacetic acid (40 μ L). To convert N-formylkynurenine to kynurenine, the tubes were incubated at 37 $^\circ\text{C}$ for 30 min, followed by centrifugation at 20,000 g for 20 min. Finally, 150 μ L of supernatant is added to 150 μ L of *p*-dimethylaminobenzaldehyde (pDMAB) (2%, v/v) in acetic acid to generate a Schiff base with kynurenine that was detected at a wavelength of 480 nm. We used NLG919 as the positive control and DMSO as the negative control to evaluate the high-throughput screening (HTS) system. IC_{50} values were determined by analyzing the data using Gen5 software (Synergy2 Multi-Mode Microplate Reader, BioTek Instruments, Inc.). Each compound was assayed in triplicate.

Calcium imaging assay. The calcium imaging assay was performed by an automated, cell-based fluorescence-imaging system (Arrayscan) by a previously reported method with slight modification. The human embryonic kidney 293 (HEK293) cells were seeded in medium containing 10% FBS and incubated at 37 °C with 5% CO₂ to a suitable quantity, and then cells were plated in poly-D-lysine-coated 96-well plates at a density of approximately 20000 cells/well for 24 h. Later, the cells were stained with 5 μM Fluo-4 AM for 60 min and subsequently washed three times with HBSS buffer. And then the cells were treated with up-to 10 μM of the tested samples in a 96-well plate containing 50 μl HBSS/well. For the bioactive compound **1**, its bioactivity was further tested at concentrations of 10, 5, 2.5, 1.25, and 0.625 μM, respectively. The purities of the tested compounds were >95%. The experiment was repeated three times. The false positive activity caused by the color of the tested samples was excluded. Calcium images of cells in HBSS buffer were acquired and analyzed using an Array Scan VTI HCS Reader (Cellomics, Thermo Scientific, Pittsburgh, PA, USA).

Figure S1. ¹H NMR spectrum of compound 1






Figure S2. ^{13}C NMR spectrum of compound 1




Figure S3. DEPT NMR spectrum of compound 1




Figure S4. HSQC spectrum of compound 1




Figure S5. HMBC spectrum of compound 1




Figure S6. ^1H - ^1H COSY spectrum of compound 1




Figure S7. NOESY spectrum of compound 1




Figure S8. HRESIMS spectrum of compound 1

Mass Spectrum SmartFormula Report


Analysis Info

Analysis Name D:\Data\MS\data\201709\pandongyan_PDY-DP-25_pos_23_01_3564.d
 Method LC_Direct Infusion_pos_70-500mz.m
 Sample Name pandongyan_PDY-DP-25_pos
 Comment

Acquisition Date 9/14/2017 4:02:13 PM
 Operator SCSIO
 Instrument maXis 255552.00029

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	180 °C
Scan Begin	70 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1500 m/z	Set Charging Voltage	0 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	err [mDa]	mSigma	rdb	e ⁻ Conf	N-Rule
489.175356	1	C25H29O10	100.00	489.175524	-0.3	-0.2	83.0	11.5	even	ok
511.157498	1	C25H28NaO10	100.00	511.157468	-0.1	-0.0	17.5	11.5	even	ok
999.324805	1	C50H56NaO20	100.00	999.325715	-0.9	-0.9	32.9	22.5	even	ok

Figure S9. IR spectrum of compound 1





Figure S10. UV spectrum of compound 1



data_xcalibur	
_audit_creation_date	2018-01-04
_audit_creation_method	'CrysAlisPro 1.171.39.33c (Rigaku OD, 2017)'
_computing_data_collection	'CrysAlisPro 1.171.39.33c (Rigaku OD, 2017)'
_computing_cell_refinement	'CrysAlisPro 1.171.39.33c (Rigaku OD, 2017)'
_computing_data_reduction	'CrysAlisPro 1.171.39.33c (Rigaku OD, 2017)'
_cell_length_a	11.9189(4)
_cell_length_b	6.59866(19)
_cell_length_c	26.7335(10)
_cell_angle_alpha	90.0
_cell_angle_beta	100.124(3)
_cell_angle_gamma	90.0
_cell_volume	2069.83(12)
_cell_measurement_temperature	100.00(10)
_cell_measurement_reflns_used	7548
_cell_measurement_theta_min	3.8600
_cell_measurement_theta_max	73.4340
_cell_oxdiff_length_a	11.9174(3)
_cell_oxdiff_length_b	6.5979(2)
_cell_oxdiff_length_c	26.7406(4)
_cell_oxdiff_angle_alpha	90.004(2)
_cell_oxdiff_angle_beta	100.1294(19)
_cell_oxdiff_angle_gamma	89.994(2)
_cell_oxdiff_volume	2069.83(9)
_cell_oxdiff_measurement_reflns_used	7656
_exptl_absorpt_correction_T_min	0.91061
_exptl_absorpt_correction_T_max	1.00000
_exptl_absorpt_correction_type	multi-scan
_exptl_absorpt_process_details	

```
;
CrysAlisPro 1.171.39.33c (Rigaku Oxford Diffraction, 2017)
Empirical absorption correction using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm.;
_oxdiff_exptl_absorpt_empirical_full_min          0.532
_oxdiff_exptl_absorpt_empirical_full_max          1.454
_oxdiff_exptl_absorpt_empirical_details;
Empirical correction (ABSPACK) includes:
- Absorption correction using spherical harmonics
- Frame scaling;
_diffrn_ambient_temperature 100.00(10)
_diffrn_ambient_environment N^2~
_diffrn_source 'Rotating-anode X-ray tube'
_diffrn_source_type 'Rigaku (Cu) X-ray Source'
_diffrn_radiation_probe x-ray
_diffrn_radiation_type 'Cu K\alpha'
_diffrn_radiation_wavelength 1.54184
_diffrn_radiation_monochromator mirror
_diffrn_measurement_device 'four-circle diffractometer'
_diffrn_measurement_device_type 'XtaLAB AFC12 (RINC): Kappa single'
_diffrn_detector 'CCD plate'
_diffrn_reflns_number 9974
_diffrn_reflns_av_R_equivalents 0.0267
_diffrn_reflns_av_sigmaI/netI 0.0287
_diffrn_reflns_limit_h_min -14
_diffrn_reflns_limit_h_max 9
_diffrn_reflns_limit_k_min -8
_diffrn_reflns_limit_k_max 8
_diffrn_reflns_limit_l_min -32
_diffrn_reflns_limit_l_max 31
```

```

_diffrn_reflms_theta_min 3.8457
_diffrn_reflms_theta_max 73.8670
_diffrn_measured_fraction_theta_max 0.9816
_diffrn_reflms_theta_full 66.9682
_diffrn_measured_fraction_theta_full 0.9970
_diffrn_orient_matrix_type 'CrysAlisPro convention (1999, Acta A55, 543-557)'
_diffrn_orient_matrix_UB_11      0.0112845000
_diffrn_orient_matrix_UB_12      0.2312972000
_diffrn_orient_matrix_UB_13      0.0070148000
_diffrn_orient_matrix_UB_21      0.0070015000
_diffrn_orient_matrix_UB_22      0.0238222000
_diffrn_orient_matrix_UB_23     -0.0566787000
_diffrn_orient_matrix_UB_31     -0.1306357000
_diffrn_orient_matrix_UB_32      0.0212824000
_diffrn_orient_matrix_UB_33     -0.0127748000
_diffrn_measurement_details;

```

List of Runs (angles in degrees, time in seconds):

#	Type	Start	End	Width	$t^{\sim}exp^{\sim}$	\w	\q	\k	\f	Frames
1	\w	-17.00	22.00	0.50	2.80	--	0.00	-57.00	-30.00	78
2	\w	-58.00	-31.00	0.50	2.80	--	0.00	-19.00	30.00	54
3	\w	-23.00	2.00	0.50	2.80	--	0.00	-19.00	30.00	50
4	\w	-89.00	-24.00	0.50	2.80	--	0.00	-57.00	-30.00	130
5	\w	-30.00	31.00	0.50	2.80	--	0.00	-82.00	30.00	122
6	\w	-25.00	5.00	0.50	2.80	--	0.00	-82.00	-150.00	60
7	\w	6.00	31.00	0.50	25.36	--	94.60	-82.00	-30.00	50
8	\w	136.00	183.00	0.50	25.36	--	94.60	0.00	-60.00	94
9	\w	6.00	115.00	0.50	25.36	--	94.60	-61.00	90.00	218


10	\w	5.00	100.00	0.50	25.36	--	94.60	-30.00	-150.00	190
11	\w	9.00	106.00	0.50	25.36	--	94.60	-30.00	120.00	194
12	\w	64.00	123.00	0.50	25.36	--	94.60	-82.00	-180.00	118
13	\w	8.00	116.00	0.50	25.36	--	94.60	-61.00	-30.00	216
14	\w	96.00	123.00	0.50	25.36	--	94.60	30.00	-30.00	54
15	\w	141.00	183.00	0.50	25.36	--	94.60	30.00	-30.00	84
16	\w	53.00	121.00	0.50	25.36	--	94.60	-82.00	-30.00	136
17	\w	7.00	125.00	0.50	25.36	--	94.60	-82.00	90.00	236
18	\w	5.00	108.00	0.50	25.36	--	94.60	0.00	-60.00	206
19	\w	39.00	64.00	0.50	25.36	--	94.60	-61.00	-180.00	50
20	\w	67.00	118.00	0.50	25.36	--	94.60	-61.00	-180.00	102
21	\w	91.00	118.00	0.50	25.36	--	94.60	-82.00	-60.00	54
22	\w	87.00	114.00	0.50	25.36	--	94.60	-82.00	60.00	54
23	\w	89.00	116.00	0.50	25.36	--	94.60	-82.00	-124.97	54;

```

_diffrn_measurement_method '\w scans'
_diffrn_oxdiff_ac3_digest_frames;
01b2acda7ae51b05d43ce613c0d38c5c4f000266271;
_diffrn_oxdiff_ac3_digest_hkl;
016084d2f544d8d9ee8649c850f30d2c7d04b9;
_space_group_IT_number 12
_space_group_crystal_system monoclinic
_space_group_name_H-M_alt 'I 1 2/m 1'
_reflns_odcompleteness_completeness 99.70
_reflns_odcompleteness_theta 66.97
_reflns_odcompleteness_iscentric 1
_chemical_oxdiff_formula 'C H O'

```

Figure S12. ¹H NMR spectrum of compound 2






Figure S13. ^{13}C NMR spectrum of compound 2





Figure S14. DEPT NMR spectrum of compound 2




Figure S15. HSQC spectrum of compound 2





Figure S16. HMBC spectrum of compound 2







Figure S17. ^1H - ^1H COSY spectrum of compound 2






Figure S18. NOESY spectrum of compound 2




Figure S19. HRESIMS spectrum of compound 2




Figure S20. IR spectrum of compound 2





Figure S21. UV spectrum of compound 2



No.	P/V	波长 (nm)	吸收值	描述
1	⊕	383.60	0.195	
2	⊕	312.80	0.357	
3	⊕	255.60	1.121	
4	⊕	203.00	1.055	

Figure S22. ^1H NMR spectrum of compound 3







Figure S23. ^{13}C and DEPT NMR spectrum of compound 3







Figure S24. HMBC spectrum of compound 3






Figure S25. ^1H - ^1H COSY spectrum of compound 3




Figure S26. NOESY spectrum of compound 3




Figure S27. HRESIMS spectrum of compound 3




Figure S28. IR spectrum of compound 3





Figure S29. UV spectrum of compound 3



No.	P/V	波长 (nm)	吸收值	描述
1	●	382.40	0.479	
2	●	285.80	2.557	
3	●	203.40	1.909	

Figure S30. Stimulation of calcium signaling in HEK293 cells by compound **1**
















Table S1. Stable conformers of compounds **2** and **3** used for ECD calculation

Conformer	Conformation	Energy (Kcal/mol)	Percent (%)
(13R,18S)-2-1		-1041599.686146	6.20
(13R,18S)-2-2		-1041599.444617	4.12
(13R,18S)-2-3		-1041599.444554	4.12
(13R,18S)-2-4		-1041600.177862	14.22

(13 <i>R</i> ,18 <i>S</i>)-2-5		-1041599.151884	2.51
(13 <i>R</i> ,18 <i>S</i>)-2-6		-1041599.535230	4.80
(13 <i>R</i> ,18 <i>S</i>)-2-7		-1041599.621387	5.56
(13 <i>R</i> ,18 <i>S</i>)-2-8		-1041600.425101	21.60
(13 <i>R</i> ,18 <i>S</i>)-2-9		-1041600.002034	10.57
(13 <i>R</i> ,18 <i>S</i>)-2-10		-1041599.777009	7.23

(13 <i>R</i> ,18 <i>S</i>)-2-11		-1041600.178552	14.24
(13 <i>R</i> ,18 <i>S</i>)-2-12		-1041599.535355	4.80
Conformer	Conformation	Energy (Kcal/mol)	Percent (%)
(13 <i>S</i> ,18 <i>S</i>)-3-1		-1041600.026507	44.67
(13 <i>S</i> ,18 <i>S</i>)-3-2		-1041598.761071	5.27
(13 <i>S</i> ,18 <i>S</i>)-3-3		-1041599.355448	14.38







(13 <i>S</i> ,18 <i>S</i>)-3-4		-1041598.363795	2.69
(13 <i>S</i> ,18 <i>S</i>)-3-5		-1041598.761699	5.27
(13 <i>S</i> ,18 <i>S</i>)-3-6		-1041598.583737	3.91
(13 <i>S</i> ,18 <i>S</i>)-3-7		-1041598.952211	7.28
(13 <i>S</i> ,18 <i>S</i>)-3-8		-1041599.403578	15.60


Table S2. Stable conformers of (13*R**,18*S**)-2 and their calculated ¹³C NMR data used for the ¹³C NMR calculation of (13*R**,18*S**)-2



conformer	E(au)	ϕE(au)	kcal/mol	ΔG(kcal/mol)	Pi	bolzt
q4_9	-1660.2789392	-1660.278939	-1041840.640970	-0.790913	3.802980	0.227284
q4_12	-1660.2785333	-1660.278533	-1041840.386264	-0.536207	2.473435	0.147824
q4_13	-1660.2785332	-1660.278533	-1041840.386201	-0.536144	2.473173	0.147809
q4_18	-1660.2776838	-1660.277684	-1041839.853195	-0.003138	1.005313	0.060082
q4_21	-1660.2788318	-1660.278832	-1041840.573576	-0.723518	3.393838	0.202832
q4_22	-1660.2765457	-1660.276546	-1041839.139026	0.711031	0.300932	0.017985
q4_25	-1660.2766060	-1660.276606	-1041839.176865	0.673192	0.320791	0.019172
q4_28	-1660.2776788	-1660.277679	-1041839.850057	0.000000	1.000000	0.059765
q4_30	-1660.2766956	-1660.276696	-1041839.233090	0.616967	0.352747	0.021082
q4_37	-1660.2765510	-1660.276551	-1041839.142352	0.707705	0.302627	0.018086
q4_40	-1660.2776839	-1660.277684	-1041839.853257	-0.003200	1.005420	0.060089
q4_47	-1660.2765459	-1660.276546	-1041839.139152	0.710905	0.300996	0.017989
					16.732251	

conformer	q4_9	q4_12	q4_13	q4_18	q4_21	q4_22	q4_25	q4_28	q4_30	q4_37	q4_40	q4_47	bolzt
no.	δC	δC	δC	δC	δC	δC	δC	δC	δC	δC	δC	δC	
1	168.4	169.25	169.25	167.58	169.3	167.65	167.56	169.97	169.91	170.03	167.58	167.65	168.85
2	127.64	126.63	126.63	128.53	126.66	128.59	128.45	127.7	127.46	127.73	128.53	128.58	127.30
3	171.26	168.59	168.59	171.57	168.59	171.54	171.53	168.73	168.74	168.7	171.57	171.54	169.73
4	107.59	107.57	107.57	107.55	107.6	107.48	107.5	107.3	107.27	107.23	107.55	107.48	107.54
4a	138.3	138.84	138.84	138.88	138.83	138.89	138.93	138.75	138.8	138.77	138.88	138.89	138.72
5	137.11	137.22	137.22	137.05	137.2	137.32	137.06	137.15	137.16	137.43	137.05	137.32	137.17
6	139.36	139.57	139.57	139.17	139.56	135.35	139.19	139.37	139.41	135.59	139.17	135.35	139.23
7	167.33	167.32	167.32	167.26	167.31	167.72	167.28	167.32	167.32	167.76	167.26	167.72	167.33
8	115.94	115.91	115.91	115.85	115.92	117.53	115.86	115.86	115.87	117.59	115.85	117.53	116.00
8a	138.55	138.35	138.35	138.58	138.36	139.28	138.56	138.49	138.47	139.2	138.58	139.28	138.49
9	192.86	193.19	193.19	192.7	193.25	192.79	192.68	192.97	193.02	193.07	192.7	192.79	193.03
9a	114.14	114.01	114.01	113.76	114.02	113.92	113.79	114.16	114.17	114.31	113.76	113.92	114.02
10	186.53	186.51	186.51	186.67	186.5	186.57	186.66	186.62	186.61	186.53	186.67	186.57	186.55
10a	130.25	130.2	130.2	130.23	130.27	129.89	130.21	130.23	130.24	129.88	130.23	129.89	130.21
11	20.08	20.11	20.11	20.05	20.12	17.12	20.05	20.09	20.09	17.12	20.05	17.12	19.93
12	57.56	57.74	57.74	56.99	57.76	56.98	56.99	57.63	57.68	57.61	56.99	56.98	57.56
13	76.62	72.83	72.83	68.95	72.29	68.95	69.05	68.83	68.7	68.77	68.95	68.95	72.50
14	50.29	50.47	50.47	47.37	49.46	47.36	47.55	47.2	47.35	47.18	47.37	47.36	49.36
15	180.16	181.14	181.14	184.49	180.73	184.44	184.63	182.06	182.02	181.96	184.48	184.44	181.51
16	32.33	33.6	33.6	33.17	33.05	33.18	33.4	33.19	33.39	33.2	33.17	33.18	33.09
17	28.76	29.53	29.53	29.32	29.72	29.31	30.09	28.91	28.87	28.89	29.32	29.31	29.31
18	65.12	67.76	67.76	63.13	65.34	63.1	64.53	61.59	63.24	61.52	63.13	63.1	65.31
19	183.29	181.84	181.84	182.98	184.03	182.98	182.79	182.97	182.91	182.97	182.98	182.98	182.92
20	55.27	54.57	54.57	55.34	54.72	55.34	55.4	55.23	55.28	55.22	55.34	55.34	54.96


Table S3. Stable conformers of (13S*,18S*)-3 and their calculated ¹³C NMR data used for the ¹³C NMR calculation of (13S*,18S*)-3



A	B	C	D	E	F
Conformer	E(au)	kcal/mol	ΔG(kcal/mol)	Pi	bolzt
q3_4	-1660.2793176	-1041840.878420	0.000000	1.000000	0.324209
q3_5	-1660.2760190	-1041838.808517	2.069903	0.030322	0.009831
q3_10	-1660.2779329	-1041840.009507	0.868912	0.230497	0.074729
q3_14	-1660.2781742	-1041840.160925	0.717494	0.297665	0.096506
q3_17	-1660.2778349	-1041839.948011	0.930408	0.207758	0.067357
q3_20	-1660.2760190	-1041838.808517	2.069903	0.030322	0.009831
q3_23	-1660.2767474	-1041839.265595	1.612825	0.065617	0.021274
q3_24	-1660.2768145	-1041839.307701	1.570719	0.070453	0.022841
q3_28	-1660.2765164	-1041839.120640	1.757779	0.051368	0.016654
q3_33	-1660.2788216	-1041840.567175	0.311245	0.591162	0.191660
q3_49	-1660.2786809	-1041840.478884	0.399535	0.509268	0.165109
				3.084430	

A	B	C	D	E	F	G	H	I	J	K	L
Conformer no.	q3_4 δC	q3_10 δC	q3_14 δC	q3_17 δC	q3_20 δC	q3_23 δC	q3_24 δC	q3_28 δC	q3_33 δC	q3_49 δC	bolzt
1	170.66	167.03	170.72	168.28	169.35	168.37	167.1	169.22	168.32	170.71	167.95
2	127.68	130.45	127.76	129.09	126.49	129.19	130.53	126.5	129.21	129.41	127.38
3	169.64	172.19	169.62	174.59	168.57	174.6	172.17	168.47	174.69	168.83	169.46
4	106.98	107.83	106.92	110.42	107.63	110.39	107.77	107.58	110.52	107.47	107.08
4a	138.58	138.29	138.59	138.7	138.85	138.72	138.31	138.8	138.63	138.83	137.26
5	137.16	137.01	137.44	137.13	137.19	137.4	137.27	137.2	137.13	137.05	135.81
6	139.38	139.1	135.59	139.49	139.57	135.63	135.34	139.58	139.5	139.32	137.48
7	167.3	167.23	167.76	167.23	167.3	167.7	167.67	167.3	167.24	167.31	165.70
8	115.86	115.83	117.58	115.89	115.92	117.65	117.51	115.94	115.91	115.92	114.98
8a	138.46	138.62	139.15	138.43	138.34	139.13	139.32	138.45	138.4	138.67	137.23
9	193.11	192.7	193.21	193.63	193.26	193.73	192.8	193.19	193.65	193.75	191.44
9a	114.07	113.82	114.22	113.46	114.04	113.61	113.98	114.04	113.4	114.7	112.87
10	186.66	186.67	186.56	186.5	186.5	186.4	186.58	186.52	186.5	186.58	184.75
10a	130.26	130.31	129.92	130.39	130.24	130.03	129.97	130.27	130.38	130.23	128.97
11	20.1	20.05	17.14	20.11	20.11	17.17	17.12	20.07	20.11	20.09	19.48
12	57.64	57.33	57.62	59.59	57.8	59.59	57.32	57.75	59.66	57.61	57.60
13	69.23	72.37	69.23	69.1	75.47	69.13	72.35	74.12	69.1	75.38	69.98
14	47.68	53.83	47.72	47.75	47.37	47.77	53.85	46.26	47.53	52.54	48.57
15	180.14	182.21	180.11	180.65	180.44	180.67	182.22	179.08	180.47	187.4	179.86
16	32.62	34.66	32.63	32.71	32.8	32.72	34.68	34.63	32.5	33.28	32.63
17	29.28	28.5	29.26	29.69	28.25	29.62	28.52	29.26	28.76	29.81	28.93
18	64.24	68.55	64.24	64.51	64.17	64.56	68.58	64.19	63.2	65.57	64.07
19	182.95	185.95	182.97	182.92	183.55	182.9	185.96	183.56	182.9	182.43	181.36
20	55.3	55.25	55.3	55.33	55.17	55.32	55.25	54.88	55.21	55.14	54.70

Table S4. DP4⁺ analysis result table for compound **2** (experimental for **2**, isomer 1 for (13S*,18S*)-**3**, isomer 2 for (13R*,18S*)-**2**)



Functional mPW1PW91		Solvent? PCM		Basis Set 6-311G(d,p)		Type of Data Unscaled Shifts		
		DP4+		0.00%	100.00%	-	-	-
Nuclei	sp2?	Experimental	Isomer 1	Isomer 2	Isomer 3	Isomer 4	Isomer 5	
C	x	162.4	168.0	168.8				
C	x	122.1	127.4	127.3				
C	x	164.3	169.5	169.7				
C	x	103.1	17.1	107.5				
C	x	134.7	137.3	138.7				
C	x	130.5	135.8	137.2				
C	x	132.7	137.5	139.2				
C	x	162.1	165.7	167.3				
C	x	111.8	115.0	116.0				
C	x	125	137.2	138.5				
C	x	187.8	191.4	193.0				
C	x	111.1	112.87	114.02				
C	x	180.9	184.75	186.55				
C	x	133.4	128.97	130.21				
C		16.6	19.48	19.93				
C		56.9	57.60	57.56				
C		62.3	69.98	72.50				
C		45.6	48.57	49.36				
C	x	175.2	179.86	181.50				
C		29.3	32.63	33.09				
C		23.2	28.93	29.31				
C		59.7	64.07	65.31				
C	x	172.9	181.36	182.92				
C		52.6	54.70	54.96				

Functional mPW1PW91		Solvent? PCM		Basis Set 6-311G(d,p)		Type of Data Unscaled Shifts		
		Isomer 1	Isomer 2	Isomer 3	Isomer 4	Isomer 5	Isomer 6	
sDP4+ (H data)		-	-	-	-	-	-	
sDP4+ (C data)		0.00%	100.00%	-	-	-	-	
sDP4+ (all data)		0.00%	100.00%	-	-	-	-	
uDP4+ (H data)		-	-	-	-	-	-	
uDP4+ (C data)		0.00%	100.00%	-	-	-	-	
uDP4+ (all data)		0.00%	100.00%	-	-	-	-	
DP4+ (H data)		-	-	-	-	-	-	
DP4+ (C data)		0.00%	100.00%	-	-	-	-	
DP4+ (all data)		0.00%	100.00%	-	-	-	-	

Table S5. DP4⁺ analysis result table for compound **3** (experimental for **3**, isomer 1 for (13S*,18S*)-**3**, isomer 2 for (13R*,18S*)-**2**)

Functional		Solvent?	Basis Set		Type of Data		
mPW1PW91		PCM	6-311G(d,p)		Unscaled Shifts		
		DP4+	87.50%	12.50%	-	-	-
Nuclei	sp2?	Experimental	Isomer 1	Isomer 2	Isomer 3	Isomer 4	Isomer 5
C	x	161	168.0	168.8			
C	x	121	127.4	127.3			
C	x	163.2	169.5	169.7			
C	x	102.1	107.1	107.5			
C	x	133.5	137.3	138.7			
C	x	129.5	135.8	137.2			
C	x	131.6	137.5	139.2			
C	x	161	165.7	167.3			
C	x	110.6	115.0	116.0			
C	x	124.1	137.2	138.5			
C	x	186.6	191.4	193.0			
C	x	109.9	112.87	114.02			
C	x	179.8	184.75	186.55			
C	x	132.3	128.97	130.21			
C		15.5	19.48	19.93			
C		55.9	57.60	57.56			
C		62.7	69.98	72.50			
C		44.5	48.57	49.36			
C	x	173.6	179.86	181.50			
C		28.1	32.63	33.09			
C		21.9	28.93	29.31			
C		59.2	64.07	65.31			
C	x	172.1	181.36	182.92			
C		51.6	54.70	55.22			

Functional		Solvent?	Basis Set		Type of Data		
mPW1PW91		PCM	6-311G(d,p)		Unscaled Shifts		
			Isomer 1	Isomer 2	Isomer 3	Isomer 4	Isomer 5
sDP4+ (H data)			-	-	-	-	-
sDP4+ (C data)			83.25%	16.75%	-	-	-
sDP4+ (all data)			83.25%	16.75%	-	-	-
uDP4+ (H data)			-	-	-	-	-
uDP4+ (C data)			58.47%	41.53%	-	-	-
uDP4+ (all data)			58.47%	41.53%	-	-	-
DP4+ (H data)			-	-	-	-	-
DP4+ (C data)			87.50%	12.50%	-	-	-
DP4+ (all data)			87.50%	12.50%	-	-	-